Literature DB >> 3393594

Studies on the metabolic pattern of propiverine in urine after single administration.

G Hüller1, K O Haustein, S Scheithauer.   

Abstract

In 11 healthy volunteers the metabolic pattern of propiverine [1; alpha, alpha-diphenyl-n-propoxy-1, 2-acetic acid-4-(1-methyl-piperidinyl)ester] was studied in urine after a single i.v. (5 mg) or oral dose (15 mg). To each dose 30.4 microCi (1.11 MBq) 14C-1 were added. The various urine fractions (0-1, 1-4, 4-8, 8-24 h) were extracted by chloroform and ethyl acetate at different pH-values and TLC was performed. The metabolites were identified by comparison of the RF-values of the radiochromatograms with those of the reference compounds after TLC using various solvent mixtures. Evidence for identity of the metabolites was additionally obtained by ester hydrolysis, ether cleavage or reduction with subsequent TLC after elution of the spots from the plate. The formed products were rechromatographed. 1 undergoes an extensive biotransformation: about 70% of the radioactive substances in urine consisted of 19 different metabolites, while 1 amounted to only 3%. Additionally, 3 acidic metabolites of unknown structure were isolated. Due to the metabolic pattern the following reactions of degradation were found: oxidation of the tertiary nitrogen in the piperidinyl moiety yielding N-oxides (40 to 50% of radioactivity), oxidation of one of the three carbon atoms of the propyl side chain, oxidation of the N-methyl group resulting in N-demethylated products, and ester cleavage. Propiverine N-oxide (20 to 25%) was determined as a major metabolite, whereas demethylated products occurred in minute amounts (1%). There was no evidence for oxidation of both phenyl moieties.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3393594

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  4 in total

1.  Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine.

Authors:  C Müller; W Siegmund; R Huupponen; T Kaila; G Franke; E Iisalo; M Zschiesche
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

2.  Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination.

Authors:  Karen May; Thomas Giessmann; Danilo Wegner; Reinhard Oertel; Christiane Modess; Stefan Oswald; Manfred Braeter; Werner Siegmund
Journal:  Eur J Clin Pharmacol       Date:  2008-07-15       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  On the pharmacokinetics and metabolism of propiverine in man.

Authors:  K O Haustein; G Hüller
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.